Senior Investor Relations Analyst
AledadeFull Time
Senior (5 to 8 years)
Candidates must possess 10+ years of experience in investor relations, finance, equity research, or investment banking. Exceptional written and verbal communication skills are essential, along with a proven ability to translate financial data into compelling narratives. A track record of managing investor relations for a high-growth or pre-IPO company, preferably in healthcare or tech, is required. Strong knowledge of capital markets, financial modeling, and valuation methodologies, as well as executive presence and comfort interfacing with senior leaders and investors, are also necessary.
The VP, Investor Relations will develop and execute a strategic IR program aligned with Virta's goals, serving as the primary liaison between the company and the investment community. This role involves leading the creation of investor materials, partnering closely with Finance, Legal, and Communications on earnings and disclosures, and monitoring market trends. The individual will organize and lead investor meetings and conferences, provide feedback to leadership on market perceptions, and ensure compliance with regulatory standards. Within the first 90 days, the focus will be on understanding the business, auditing existing IR materials, building relationships, designing an IR strategy roadmap, and leading an investor update.
Reverses type 2 diabetes through personalized care
Virta Health focuses on reversing type 2 diabetes through a combination of personalized nutrition, continuous remote care, and behavioral science. Their treatment is designed for individuals diagnosed with type 2 diabetes, healthcare providers, and enterprise partners like employers and health plans. Unlike many competitors, Virta Health operates on a performance-based model, meaning they only receive payment if they achieve successful outcomes for their patients. This aligns their financial incentives with patient health improvements. The company's goal is to reverse type 2 diabetes in 100 million people, making their approach not just about managing diabetes but actively working towards its reversal.